Warnex Inc.

Warnex Inc.

March 01, 2006 07:03 ET

Warnex signs up U.S. service lab, AmeriSci Bio-Chem

LAVAL, QC, March 1 - Warnex Inc. (TSX:WNX) announced today that
AmeriSci Bio-Chem, a leading scientific service laboratory based in
Midlothian, Virginia, will offer real-time PCR pathogen testing services using
the Warnex™ Rapid Pathogen Detection System. AmeriSci Bio-Chem will use
Warnex's food safety technology to test for strains of E. coli O157, Listeria
and Salmonella.

AmeriSci Bio-Chem (www.ameriscibiochem.com) is a national independent
third party laboratory that provides testing services in the areas of
environmental microbiology, food safety, and molecular biology, with offices
in Richmond, Boston, Manhattan, and Los Angeles. The company offers routine
microbiology services to all food industries, including testing of raw
ingredients, environmental samples, and finished products, providing clients
with effective data about their in-house quality and safety. With major
accreditations from the American Association for Laboratory Accreditation
(A2LA) and the American Industrial Hygiene Association (AIHA), AmeriSci
Bio-Chem adheres to all FDA and USDA testing guidelines.

The Warnex Rapid Pathogen Detection System uses cutting-edge DNA-based
technology to rapidly and accurately determine the presence of pathogens in a
sample. The system allows for the simultaneous detection of multiple pathogens
and processing of samples within 3 to 48 hours, a significant improvement over
traditional microbiology tests that currently require 5 to 7 days.

About Warnex

Warnex (www.warnex.ca) is a biotechnology company devoted to protecting
public health by providing advanced diagnostic products and science-based
services to the agri-food, pharmaceutical and healthcare sectors. Warnex's
genomics-based technology offers a versatile detection platform that produces
accurate results rapidly, using Real-Time PCR technology combined with unique
genetic markers and software. With a focus on pathogen detection in food, our
development pipeline also includes applications in GMO testing, meat
speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex's analytical, bioanalytical, and clinical service groups offer a
variety of quality control services, method development and validation,
contract R&D, bioavailability and bioequivalence studies for clinical trials,
and medical laboratory testing.

Warnex is a trademark of Warnex Inc.


Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, manufacturing and laboratory facilities, suppliers,
key employees, key customers, financial resources and credit risk, government
regulations, foreign currency risk and volatility of share price, and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to the
heading Risks and Uncertainties in the Management's Discussion and Analysis
for the third quarter ended on September 30, 2005, which can be found at
www.sedar.com. Consequently, actual results may differ materially from the
anticipated results expressed in these forward-looking statements.

Contact Information